Physician profile
Marc Alan Silver
NPI 1992818520
$173,491.61
in general payments reported to CMS, 2019-2025
14 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2021: $5,000 · 2022: $9,441 · 2023: $150 · 2024: $78K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $156K · Food and Beverage: $1,670 · Travel and Lodging: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,000.00 |
| Food and Beverage | $1,670.24 |
| Travel and Lodging | $732.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daxor Corporation | $156,000.00 | 2024-2025 | Bva-100 |
| Impulse Dynamics (USA) INC. | $15,923.60 | 2021-2025 | Optimizer |
| Medicure Pharma INC. | $615.02 | 2019 | |
| Becton, Dickinson and Company | $172.05 | 2025 | |
| Abiomed | $161.90 | 2024-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $155.06 | 2025 | |
| Daiichi Sankyo INC. | $132.70 | 2023 | Injectafer |
| Cardiac Dimensions, INC. | $90.40 | 2024 | |
| Scpharmaceuticals INC. | $75.43 | 2025 | |
| Livanova USA, INC. | $41.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.28 | 2024 | Wainua |
| Pfizer INC. | $35.74 | 2023-2025 | |
| Boston Scientific Corporation | $32.46 | 2019 | |
| Picard Medical INC. | $17.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.